J9173 Injection., durvalumab, 10 milligrams
Also known as: durvalumab, Imfinzi
Intravenous injection of durvalumab, a human monoclonal antibody targeting programmed death ligand-1 (PD-L1), dosed per 10 milligrams.
In Plain Language
immune checkpoint inhibitor; lung cancer immunotherapy
Clinical Context
Used for unresectable stage III non-small cell lung cancer and advanced bladder cancer, blocking PD-L1 immune checkpoint.
RVU Information
CPT J9173 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9173?
CPT J9173 (Injection., durvalumab, 10 milligrams) is a J Codes (Drugs) code. Intravenous injection of durvalumab, a human monoclonal antibody targeting programmed death ligand-1 (PD-L1), dosed per 10 milligrams.
How is J9173 administered?
CPT J9173 is administered by a healthcare provider, typically via injection or infusion. Used for unresectable stage III non-small cell lung cancer and advanced bladder cancer, blocking PD-L1 immune checkpoint. It is used by Oncology, Pulmonary Oncology.
When is CPT J9173 used?
Used for unresectable stage III non-small cell lung cancer and advanced bladder cancer, blocking PD-L1 immune checkpoint.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.